thoracic_website_laptop_19
thoracic_website_phone_19

Schedule of Events

Individual presenter disclosures will be linked to their names in the Schedule of Events below. You will also be able to view all presenter disclosures at once.

[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist


Wednesday, March 13, 2019

4:00 p.m. - 6:00 p.m.
Registration

Thursday, March 14, 2019

7:00 a.m. - 5:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:50 a.m. - 8:00 a.m.
Day One Welcome
Jessica S. Donington, MD, New York University Cancer Center, New York [S]

8:00 a.m. - 9:15 a.m.
General Session I: Lung Cancer Screening and Diagnosis
Moderator: Lecia V. Sequist, MD, MPH, Massachusetts General Hospital, Boston [M]

  • Why Has Screening Not Been More Widely Adopted?
    Renda Soylemez Wiener, MD MPH, Boston University, Boston [Pulmonologist]
  • Radiomics and Radiogenomics in Lung Cancer Diagnosis
    Ann Leung, MD, Stanford University Medical Center, Stanford, California [Radiologist]
  • Advanced Bronchoscopic and Targeting Techniques for Diagnosis
    Jamie L. Bessich, MD, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York [S]
  • Early Detection Using Blood and Breath Biomarkers
    Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist] 
  • Questions and Answers

9:15 a.m. - 9:30 a.m.
Break

9:30 a.m. - 10:15 a.m.
Keynote I: Updates from the National Lung Cancer Round Table
Moderator: Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]
Speaker: Ella A. Kazerooni, MD, University of Michigan, Ann Arbor, Michigan [Diagnostic Radiologist]

10:15 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:15 p.m.
Plenary Session
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]

12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Expert Office Hours

1:15 p.m. - 2:45 p.m.
General Session II: Early Stage Thoracic Cancers
Moderator: Jessica S. Donington, MD, New York University Cancer Center, New York [S]

  • Surgical Options for Stage I NSCLC, Including Synchronous and Metachronous Primaries: Pros and Cons
    Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S]
  • Radiation Therapy Including SBRT for Stage I NSCLC – Pros and Cons
    Jing Zeng, MD, University of Washington, Seattle [R]
  • The Medical Oncologist and Stage I NSCLC: Is There a Role for Adjuvant and/or Neoadjuvant Therapy?
    Hatim Husain, MD, University of California San Diego, La Jolla, California [M]
  • Early Stage Tumor Board
  • Questions and Answers

2:45 p.m. - 3:15 p.m.
Coffee Break

3:15 p.m. - 5:00 p.m.
General Session III: Locally Advanced Stage III Cancer
Moderator: Jeffrey D. Bradley, MD, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis [R]

  • Systemic Therapy: Induction, Consolidation, Immunotherapy
    Jyoti Patel, MD, University of Chicago [M]
  • Does Surgery Have a Role in Stage III NSCLC?
    Mark W. Onaitis, MD, UC San Diego Health, La Jolla, California [S]
  • Neoadjuvant or Adjuvant Radiotherapy for Stage III NSCLC?
    Cecile Le Péchoux, MD, Institut de Cancérologie Gustave Roussy, Villejuif, France [R]
  • Definitive Chemoradiotherapy in Stage III NSCLC
    Arya Amini, MD, City of Hope, Duarte, California [R]
  • Locally Advanced Tumor Board
    • Additional panelist: Peter Mazzone, MD, MPH, Cleveland Clinic, Cleveland [Pulmonologist]
  • Q&A/Discussion

5:00 p.m. - 6:00 p.m.
Poster Viewing Session and Reception

Friday, March 15, 2019

7:00 a.m. - 4:30 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Two Welcome
Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]

8:00 a.m. - 9:15 a.m.
General Session IV: Evaluation, Prehabilitation, ERAS, and Quality of Life
Moderator: Richard Whyte, MD, Beth Israel Deaconess Medical Center, Boston [S]

  • Frailty, Resiliency, and Treatment Decisions
    Mark K. Ferguson, MD, University of Chicago, Chicago [S]
  • ERAS in Lung Resection: What Non-surgeons Need To Know
    Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S]
  • Patient Reported Outcomes for NSCLC Therapy
    Benjamin Movsas, MD, Henry Ford Health System, Detroit [R]
  • Supportive and End-of-Life Care
    Lauren Hertan, MD, MS, Beth Israel Deaconess Medical Center, Boston [Supportive Care Expert]
  • Questions and Answers

9:15 a.m. - 9:30 a.m.
Break

9:30 a.m. - 10:15 a.m.
Keynote II: Opioid Use and Cancer Patients’ Pain Management
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
Speaker: Eduardo Bruera, MD, FAAHPM, MD Anderson Cancer Center, Houston [M]

10:15 a.m. - 10:45 a.m.
Coffee Break

10:45 a.m. - 12:15 p.m.
Oral Abstract Session
Moderator: Melanie Edwards, MD, St. Joseph Mercy/IHA Thoracic Surgery, Ypsilanti, Michigan [S]

12:15 p.m. - 1:15 p.m.
Lunch in the Exhibit Hall
Trainee and Early-career Networking Luncheon

Speakers:

  • Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]
  • Linda W. Martin, MD, MPH, FACS, FCCP, University of Virginia Health System, Charlottesville, Virginia [S]
  • Sue Yom, MD, PhD, University of California, San Francisco [R]

1:15 p.m. - 2:15 p.m.
General Session V: Rare Thoracic Cancers
Moderator: Aaron S. Mansfield, MD, Mayo Clinic, Rochester, Minnesota [M]

  • Mesothelioma
    Anne S. Tsao, MD, MD Anderson Cancer Center, Houston [M]
  • Thymic Epithelial Tumors
    Heather Wakelee, MD, Stanford University, Stanford, California [S]
  • Novel Imaging and Treatments in Neuroendocrine Tumors
    Andrei H. Iagaru, MD, Stanford School of Medicine, Stanford, California [Nuclear Medicine Physician]
  • Questions and Answers

2:15 p.m. - 2:45 p.m.
Coffee Break

2:45 p.m. - 4:30 p.m.
General Session VI: Advanced Non-small Cell Lung Cancer
Moderator: Shirish M. Gadgeel, MD, University of Michigan, Ann Arbor, Michigan [M]

  • Integrating Chemotherapy and Immune Therapy
    Thomas Eldridge Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina [M]
  • Current State-of-the-Art for EGFR+ and ALK+ Patients
    Heather Wakelee, MD, Stanford University, Stanford, California [M]
  • Emerging Targeted Therapies
    Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York [M]
  • Oligometastatic Disease – Treatment Options
    Daniel R. Gomez, MD, MD Anderson Cancer Center, Houston [R]
  • Advanced Non-small Cell Lung Cancer Tumor Board
  • Questions and Answers 

Saturday, March 16, 2019

7:00 a.m. - 12:00 p.m.
Registration

7:00 a.m. - 8:00 a.m.
Continental Breakfast

7:55 a.m. - 8:00 a.m.
Day Three Welcome
Ramesh Rengan, MD, PhD, University of Washington, Seattle [R]

8:00 a.m. - 9:00 a.m.
General Session VII: What’s New in Small Cell Lung Cancer?
Moderator: Ravi Salgia, MD, PhD, City of Hope, Duarte, California [M]

  • Current Radiation Management of Small Cell
    Jeffrey A. Bogart, MD, State University of New York, New York [R]
  • Current Medical Management of Small Cell
    Ticiana A. Leal, MD, University of Wisconsin, Madison, Wisconsin [M]
  • Emerging Approaches
    Helen J. Ross, MD, Mayo Clinic, Scottsdale, Arizona [M]
  • Questions and Answers

9:00 a.m. - 9:15 a.m.
Break

9:15 a.m. - 10:45 a.m.
General Session VIII: Special Topics in Immunotherapy
Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R]

  • Radiation and Immunotherapy: The Inflammation Perfect Storm
    Sean Park, MD, MS, PhD, Mayo Clinic, Rochester, Minnesota [R]
  • Immunotherapy and Brain Metastases
    Sarah B. Goldberg, MD, MPH, Yale Cancer Center, New Haven, Connecticut [M]
  • Hyperprogression in Patients on Immunotherapy
    Christophe Le Tourneau, MD, PhD, Institut Curie, Paris [M]
  • Immunotherapy Tumor Board
  • Q&A/Discussion

10:45 a.m. - 11:00 a.m.
Break

11:00 a.m. - 12:00 p.m.
General Session IX: Management of Immunotherapy Toxicities
Moderator: Nathan A. Pennell, MD, PhD, Cleveland Clinic, Cleveland [M]

  • Pulmonary Toxicities of Chemotherapy and Immunotherapy for NSCLC
    M. Patricia Rivera, MD, UNC School of Medicine, Chapel Hill, North Carolina [Pulmonologist]
  • Safety of Immunotherapy in Patients with Autoimmune Disease
    Martin J. Edelman, MD, Fox Chase Cancer Center, Philadelphia [M]
  • Toxicities of Immunotherapy Combined with Targeted Therapies
    Leora Horn, MD, MSc, Vanderbilt University, Nashville, Tennessee [M]
  • Questions and Answers
Copyright © 2016 American Society for Radiation Oncology | Conflict of Interest | Terms of Use | Privacy Policy | Contact Us 
251 18th Street South, 8th Floor, Arlington, VA 22202 | Phone: 703.502.1550 | Fax: 703.502.7852